Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Silvia Luppi"'
Autor:
Chiara Casotti, Claudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, Leonardo Fantoni, Michela Pasello, Katia Scotlandi, Toni Ibrahim, Massimo Serra
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Methotrexate (MTX) is one of the most important drugs included in the first-line protocols to treat high-grade osteosarcoma (HGOS). Although several polymorphisms have been reported to be associated with drug response or MTX-related tox
Externí odkaz:
https://doaj.org/article/8139d9c37b0e48caa53e1ce404be4871
Autor:
Claudia Maria Hattinger, Chiara Casotti, Maria Pia Patrizio, Silvia Luppi, Leonardo Fantoni, Katia Scotlandi, Toni Ibrahim, Massimo Serra
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11787 (2022)
Cisplatin (CDDP) is a drug for high-grade osteosarcoma (HGOS) treatment. Several germline pharmacogenetic studies have revealed associations between single nucleotide polymorphisms (SNPs) and CDDP-based therapy response or CDDP-related toxicity in pa
Externí odkaz:
https://doaj.org/article/b1a39508e9114e5eb1e900ab941b038d
Autor:
Marilù Fanelli, Elisa Tavanti, Maria Pia Patrizio, Serena Vella, Amira Fernandez-Ramos, Federica Magagnoli, Silvia Luppi, Claudia Maria Hattinger, Massimo Serra
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Treatment of high-grade osteosarcoma, the most common malignant tumor of bone, is largely based on administration of cisplatin and other DNA damaging drugs. Altered DNA repair mechanisms may thus significantly impact on either response or resistance
Externí odkaz:
https://doaj.org/article/4774680e434c48448ec5a816bd0cd9a2
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 13, p 4659 (2020)
High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providi
Externí odkaz:
https://doaj.org/article/4e1f1ad5c890483cbe2b82876d9eea4c
Publikováno v:
Expert Opinion on Emerging Drugs. 24:153-171
Introduction: Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operat
Autor:
Claudia Maria Hattinger, Massimo Serra, Maria Pia Patrizio, Silvia Luppi, Piero Picci, Federica Magagnoli, Elisa Tavanti
Publikováno v:
Expert Review of Molecular Diagnostics. 18:947-961
Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered: This review provides an overview of the state of a
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 4659, p 4659 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providi
Autor:
Claudia Maria Hattinger, Silvia Luppi, Massimo Serra, Amira Fernandez-Ramos, Federica Magagnoli, Elisa Tavanti, Serena Vella, Maria Pia Patrizio, Marilù Fanelli
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Treatment of high-grade osteosarcoma, the most common malignant tumor of bone, is largely based on administration of cisplatin and other DNA damaging drugs. Altered DNA repair mechanisms may thus significantly impact on either response or resistance